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Despite tremendous advances in ourunderstanding of the molecular basis ofdiseases such as cancer, substantial gapsremain both in our understanding of disease pathogenesis and in the development
of effective strategies for early diagnosis and for 
treatment. The current interest in proteomics is due in
part to the prospects that a proteomic approach to 
disease investigations will overcome some of the
limitations of other approaches1. The opportunities as
well as the challenges facing disease proteomics are
formidable. Particularly promising areas of research
include: delineation of altered protein expression, not 
only at the whole-cell or tissue levels, but also in
subcellular structures, in protein complexes and in
biological fluids; the development of novel biomarkers for
diagnosis and early detection of disease; and the
identification of new targets for therapeutics and the
potential for accelerating drug development through more
effective strategies to evaluate therapeutic effect and
toxicity. 
The dynamic nature of the proteome of a cell or a tissue
provides ample justification for studying gene expression in
disease directly at the proteomic level. But capturing this
dynamic state represents a technological challenge.
Undoubtedly, tackling the numerous facets of disease 
proteomics requires implementation of multiple strategies
and technology platforms.
Proteome profiling technologies are currently evolving
in a manner that emphasizes the need for sensitivity and
throughput. No one technology is likely to emerge that 
will meet the needs of all types of proteomics-based investi-
gations, from expression proteomics to functional 
proteomics, particularly as they relate to disease.
The use of two-dimensional gels
During the early years of proteomics and until relatively
recently, profiling of protein expression in disease relied
primarily on the use of two-dimensional polyacrylamide
gel electrophoresis (2D PAGE), which was later combined
with mass spectrometry2. Most studies of this nature 
followed an approach in which a cocktail was used to 
solubilize the protein contents of an entire cell population,
tissue or biological fluid, followed by separation of the 
protein contents of the lysate using 2D gels and visualiza-
tion of the separated proteins using silver staining. It
became clear that such an approach allows only a limited
display of protein content that consisted of relatively abun-
dant proteins. Nevertheless, profiling of disease tissues
using this approach has had some utility. For example, it
was demonstrated long before the use of DNA microarrays
that leukaemias could be classified into their different sub-
types using 2D PAGE3.
Numerous other studies have also identified disease-
related changes in protein expression, primarily using 
2D PAGE and mass spectrometry. One such example is
provided by studies of heart disease4, the spectrum of
which encompasses a broad set of pathological conditions,
some with acute onset of severe disease and others with
slow, chronic progression. To assist in data gathering and
mining, online 2D gel-derived databases of protein expres-
sion in the myocardium for human and other species were
constructed5,6. These databases have allowed investigators
to compare data and establish reference standards. 
Relevant findings have emerged from studies of changes in
myocardial proteins associated with human heart failure as
well as from studies of animal models of heart failure and of
isolated rat myocytes4. Although only a small proportion of
the proteome has been analysed, pronounced changes in
the composition of the cardiac proteome have been found,
affecting proteins with diverse functions. Altered overall
levels of specific proteins or altered post-translational
modifications of proteins such as myosin light chain 2 
have been reported in the failing heart7. And protein
expression studies have uncovered proteins that exhibited
new disease-related post-translational modifications with
predicted functional relevance8–11. This level of progress
typifies that made in profiling disease tissue in a wide 
variety of diseases.
An important development in 2D PAGE is the use 
of immobilized pH gradients (IPGs) in which the pH 
gradient is fixed within the acrylamide matrix. IPGs also
allow production of gels that cover a defined pH range,
from wide to narrow12,13. A variation on this theme is 
the use of so-called ‘zoom gels’ in which the protein 
contents of an individual sample are first fractionated into
narrow pH ranges under low resolution, and then 
each fraction undergoes high-resolution separation by 2D
PAGE14. For example, the pre-fractionation of serum using
this approach has enhanced the ability to detect low-
abundance and potentially new circulating disease-marker
proteins14. Yet another innovation in 2D gels is the use of
differential in-gel electrophoresis (DIGE), in which 
two pools of proteins are labelled with different 
fluorescent dyes15. The labelled proteins are mixed and 
separated in the same 2D gel. In one study16, 2D DIGE 
was applied to quantify the differences in protein expres-
sion between oesophageal carcinoma cells and normal 
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The sequencing of the human genome and that of numerous pathogens has opened the door for proteomics
by providing a sequence-based framework for mining proteomes. As a result, there is intense interest in
applying proteomics to foster a better understanding of disease processes, develop new biomarkers for
diagnosis and early detection of disease, and accelerate drug development. This interest creates numerous
opportunities as well as challenges to meet the needs for high sensitivity and high throughput required for
disease-related investigations.
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epithelial cells. A large number of proteins were found to be either
upregulated or downregulated in cancer cells.
Sample fractionation prior to analysis
Some of the main challenges facing expression proteomics, be it
using 2D PAGE or any other approach, include the great dynamic
range of protein abundance and a wide range of protein properties,
including mass, isoelectric point, extent of hydrophobicity and 
post-translational modifications. Reducing sample complexity prior
to analysis — for example, by analysing protein subsets and subcellu-
lar organelles separately — improves the reach of 2D gels or other
separation techniques for the quantitative analysis of low-abundance
proteins. An elegant demonstration of the power of sub-proteome
analysis is illustrated in studies of phagosomes17; these have led to the
identification of over 250 proteins from this organelle and the
demonstration that phagosomes are formed by direct association
and fusion of endoplasmic reticulum to the plasma membrane 
during early phagocytosis.
The isolation of sub-proteomes may be combined with protein
tagging to further enhance sensitivity, as in the case of surface-
membrane proteins, a compartment rich in diagnostic and 
therapeutic targets. Protein tagging technologies are currently being
implemented for the comprehensive analysis of the cell-surface 
proteome (Fig. 1). A surface-protein biotinylation strategy, coupled
with the use of mass spectrometry, was applied to the gastric
pathogen Helicobacter pylori, leading to the identification of new 
surface-membrane proteins18. This strategy has also led to the 
detection and identification of many new proteins on the surface of
cancer cells (Fig. 1)19.
Beyond 2D gels for disease expression profiling
Even with all the improvements that could be introduced, 2D gels will
probably remain a rather low-throughput approach that requires a
relatively large amount of sample. The latter is particularly problem-
atic for clinical samples, as such samples are generally procured in
limited amounts. Furthermore, tissue heterogeneity complicates the
analysis of clinical samples. Various tissue microdissection
approaches are beneficial to reduce heterogeneity, but they further
reduce the amount of sample available. In particular, the use of 
laser-capture microdissection, which allows defined cell types to be
isolated from tissues, yields amounts of proteins that are difficult to
reconcile with the need for greater amounts for 2D gels1.
Undoubtedly, various non-gel-based schemas that rely on liquid-
based separations of proteins or peptides, with or without tagging,
will have utility for disease proteomics, particularly given their
potential for automation. Additionally, advances in microfluidic
technology will likely allow automated separation of proteins in
complex lysates using much reduced sample amounts. Microfluidic
systems already have been integrated with mass spectrometry for
protein digestion and identification20.
Non-separation-based strategies, including direct profiling using
mass spectrometry or the use of protein microarrays, are important
developments. Mass spectrometry has been applied to the in situ pro-
teomic analysis of tissues, an approach that allows imaging of protein
expression in normal and disease tissues21. By this method, frozen tis-
sue is sliced and sections are applied on a matrix-assisted laser des-
orption/ionization (MALDI) plate and analysed at regular spatial
intervals. The mass spectra obtained at different intervals are com-
pared, yielding a spatial distribution of individual masses across the
tissue section (Fig. 2). Mass profiles of tissue sections obtained from
normal and disease tissues may be compared to detect altered protein
expression. Tumour analyses using this approach have uncovered
differences in protein expression between normal and tumour tissues
that may have specificity for different tumour types21.
DNA and protein microarrays in disease investigation
Cancer profiling using DNA microarrays
Profiling gene expression using DNA arrays has had a tremendous
impact on biomedical research. Disease-related applications of DNA
microarrays include uncovering unsuspected associations between
genes and specific clinical features of disease that are helping devise
new molecular-based classifications of disease. In relation to cancer,
most published studies of tumour analysis using DNA microarrays
have examined pathologically homogeneous sets of tumours to 
identify clinically relevant subtypes (for example, responders versus
non-responders), pathologically distinct subtypes of tumours of the
same lineage to identify molecular correlates (for example, high-
stage versus low-stage tumours), or tumours of different lineages to
identify molecular signatures for each lineage.
Published studies of breast cancer illustrate the potential contri-
bution of DNA microarrays to uncover new disease subtypes. In one
study, tumours could be classified into a basal epithelial-like group,
an ErbB2-overexpressing group and a normal breast-like group22. In
a later study, survival analyses on a sub-cohort of patients with locally
advanced breast cancer showed significantly different outcomes for
patients belonging to the various groups, despite uniform 
treatment23. In an independent study of 38 invasive breast cancers,
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Figure 1 Affinity capture of surface-membrane proteins. Biotinylation reagents
provide a ‘tag’ that transforms poorly detectable surface-membrane proteins into
probes that can be recognized by a labelled detection reagent. a, Intact cells are
tagged using lipid-insoluble biotin reagents. Tagged proteins are captured after cell
lysis using avidin columns and subsequently eluted. Following a separation step using
2D gels or other means, tagged proteins are detected with a labelled avidin conjugate.
Individual proteins are identified by mass spectrometry. b, Close-up section of a 2D
pattern in which biotinylated proteins are selectively visualized (top) in contrast with
the pattern of the same whole-cell lysate visualized by silver staining (bottom). Several
selectively visualized proteins were found to have chaperone functions19.
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striking molecular differences between ductal carcinoma specimens
were uncovered that led to a suggested new classification for oestro-
gen-receptor (ER)-negative breast cancer24. Similarly, a study of 
58 node-negative breast carcinomas discordant for ER status also
uncovered a list of genes that discriminated tumours according to ER
status25. More recently, gene expression profiling was found to be a
more powerful predictor of disease outcome in young patients with
cancer than clinical- and histological-based classifications26.
DNA versus protein microarrays
The DNA microarray studies described above, as well as numerous
others in the literature, indicate the great utility of DNA microarrays
for uncovering patterns of gene expression that are clinically infor-
mative. An important challenge for microarray analysis of disease tis-
sues and cells is to understand at a mechanistic level the significance
of associations observed between subsets of genes and clinical fea-
tures of disease. Another challenge is to identify the smallest but most
informative sets of genes associated with specific clinical features,
which then can be interrogated using technologies available in clini-
cal laboratories. Yet another challenge is to determine how well RNA
levels of predictive genes correlate with protein levels. A lack of 
correlation may imply that the predictive property of the gene(s) is
independent of gene function. For example, comparisons of messen-
ger RNA and protein levels for the same tumours reported for lung
cancer demonstrated that only a small percentage of genes had a 
statistically significant correlation between the levels of their 
corresponding proteins and mRNAs27.
Technologies for DNA microarray analysis are still evolving.
There is a tendency by manufacturers to favour oligonucleotide- over
complementary DNA-based microarrays, and progress has been
made on adoption of data analysis standards28. Nevertheless, 
however perfected DNA microarrays and their analytical tools
become for disease profiling, they will not eliminate a pressing need
for other types of profiling technologies that go beyond measuring
RNA levels, particularly for disease-related investigations. DNA
microarrays have limited utility for the analysis of biological fluids
and for uncovering assayable biomarkers directly in the fluid.
Numerous alterations may occur in proteins that are not reflected in
changes at the RNA level, providing a compelling rationale for direct
analysis of gene expression at the protein level. As a result, there is
substantial interest in developing microarrays or biochips that allow
the systematic analysis of thousands of proteins (see review in this
issue by Fields and co-workers, page 208).
Unlike DNA microarrays, which provide one measure of gene
expression (namely RNA levels), there is a need to implement protein
microarray strategies that address the many different features of pro-
teins that can be altered in disease. These include, on the one hand,
determination of their levels in biological samples and, on the other,
determination of their selective interactions with other biomolecules,
such as other proteins, antibodies, drugs or various small ligands. The
compelling need for protein chips has led numerous biotechnology
companies to devise new strategies for producing biochips that have
utility for biomedical investigations. New classes of capture agents
include aptamers (SomaLogic, http://www.somalogic.com/),
ribozymes (Archemix, http://www.archemix.com/), partial-mole-
cule imprints (Aspira Biosystems, http://www.aspirabio.com) and
modified binding proteins (Phylos, http://www.phylos.com). For
assays of protein interaction, biochips that contain either peptides or
proteins are being produced. Peptides may be synthesized in very large
numbers directly on the chip29. Alternatively, recombinant proteins
may be arrayed and effort is underway to assemble large sets of puri-
fied recombinant proteins for microarrays and other applications.
Profiling studies of disease tissue that have used protein micro-
arrays are beginning to emerge. As a model to better understand how
patterns of protein expression shape the tissue microenvironment,
Knezevic et al. analysed protein expression in tissue derived from
squamous cell carcinomas of the oral cavity through an antibody
microarray approach for high-throughput proteomic analysis30.
Using laser-capture microdissection to procure total protein from
specific microscopic cellular populations, they showed that quantita-
tive, and potentially qualitative, differences in expression patterns of
multiple proteins within epithelial cells correlated reproducibly with
oral-cavity tumour progression. Differential expression of multiple
proteins was found in stromal cells surrounding and adjacent to
regions of diseased epithelium that correlated directly with tumour
progression of the epithelium. Most of the proteins identified in both
cell types were involved in signal transduction pathways. Knezevic et
al. hypothesized therefore that extensive molecular communications
involving complex cellular signalling between epithelium and 
stroma play a key role in driving progression of oral-cavity cancer.
A reverse-phase protein array approach that immobilizes the
whole repertoire of a tissue’s proteins has been developed31. A high
degree of sensitivity, precision and linearity was achieved, making it
possible to quantify the phosphorylated status of signal proteins in
subpopulations of human tissue cells. Using this approach, Paweletz
et al.31 performed a longitudinal analysis of the state of pro-survival
checkpoint proteins at the microscopic transition stage from patient-
matched, histologically normal prostate epithelium to prostate
intraepithelial neoplasia and to invasive prostate cancer. Cancer 
progression was associated with increased phosphorylation of the
serine/threonine kinase Akt, suppression of apoptosis pathways, and
decreased phosphorylation of extracellular signal-regulated kinase
(ERK). At the transition from histologically normal epithelium to
intraepithelial neoplasia, a statistically significant surge in 
phosphorylated Akt was observed, together with a concomitant 
suppression of downstream apoptosis pathways preceding the 
transition into invasive carcinoma.
A clinically relevant application of protein microarrays is the
identification of proteins that induce an antibody response in
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Figure 2 Imaging mass spectrometry. Transverse sections of rat brain were cut,
thaw-mounted on the target plate and coated with matrix21. A survey scan was
performed first with data acquisition taken randomly across the section to generate an
average protein profile. Over 200 individual mass peaks were detected in a mass-to-
charge (m/z ) range of up to 40,000. The figure presents an optical image of the brain
section prior to matrix deposition. The section was scanned by acquiring 74275
points with a resolution of 180 mm by averaging spectra produced by 15 laser shots
using an automated imaging computer algorithm. In this scan, the intensity of all of
the different mass signals was monitored. Fifteen ion-density maps are shown, each
obtained for different protein signals; some of these, in particular m/z 6,844, have low
intensities. As expected, some proteins were found to be highly specific for a given
brain region. This is particularly striking for the density maps of the proteins detected
at m/z 5,631 and m/z 18,388, which are almost ‘negatives’ of each other.
© 2003 Nature Publishing Group
autoimmune disorders32. Microarrays were produced by attaching
several hundred proteins and peptides to the surface of derivatized
glass slides. Arrays were incubated with patient serum, and 
fluorescent labels were used to detect autoantibody binding to 
specific proteins in autoimmune diseases, including systemic lupus
erythematosus and rheumatoid arthritis. Such microarrays 
represent a powerful tool to study immune responses in a variety of
diseases, including cancer.
One of the main challenges in making biochips for global analysis
of protein expression is the current lack of comprehensive sets of
genome-scale capture agents such as antibodies. Another important
consideration in protein microarrays is that proteins undergo
numerous post-translational modifications that may be crucial to
their functions. But these modifications are generally not captured
using either recombinant proteins or antibodies that do not 
distinctly recognize specific forms of a protein. One approach for
comprehensive analysis of proteins in their modified forms is to array
proteins isolated directly from cells and tissues following protein
fractionation schemes33. Fractions that react with specific probes are
within the reach of chromatographic and gel-based separation 
techniques for resolving their individual protein constituents, and of
mass spectrometric techniques for identification of their constituent
proteins. Protein microarrays of different types are likely to become
commercially available for clinically relevant assays of broad sets of
proteins and may well rival DNA microarrays for introduction into
the clinical laboratory.
The quest for disease biomarkers using proteomics
There is substantial interest in applying proteomics to the identifica-
tion of disease markers. Approaches include comparative analysis of
protein expression in normal and disease tissues to identify aberrant-
ly expressed proteins that may represent new markers, analysis of
secreted proteins in cell lines and primary cultures, and direct serum
protein profiling. The potential of mass spectrometry to yield 
comprehensive profiles of peptides and proteins in biological fluids
without the need to first carry out protein separations has attracted
interest. In principle, such an approach is highly suited for marker
identification because of reduced sample requirements and high
throughput.
This approach is currently popularized, particularly for serum
analysis, by the technology referred to as surface-enhanced laser 
desorption/ionization1. Microlitre quantities of serum from many
samples are applied to the surface of a protein-binding plate, with
properties to bind a class of proteins. The bound proteins are treated
and analysed by MALDI. The mass spectra patterns obtained for 
different samples reflect the protein and peptide contents of these
samples. Patterns that distinguish between cancer patients and 
normal subjects with remarkable accuracy have been reported for
several types of cancer1. The main drawbacks of direct analysis of 
tissues or biological fluids by MALDI are the preferential detection of
proteins with a lower molecular mass and the difficulty in determin-
ing the identity of proteins owing to post-translational modifications
obscuring the correspondence of measured and predicted masses.
Occasionally the masses observed match precisely the predicted
masses of specific proteins. This was the case in a study of proteins
secreted by stimulated CD8 T cells, which led to the identification of
the small proteins a-defensin 1, 2 and 3 as contributing to the anti-
HIV-1 activity of CD8 antiviral factor34.
A productive approach for the identification of cancer markers
has been the analysis of serum for autoantibodies against tumour
proteins. There is increasing evidence for an immune response to
cancer in humans, demonstrated in part by the identification of
autoantibodies against a number of intracellular and surface anti-
gens detectable in sera from patients with different cancer types35.
The identification of panels of tumour antigens that elicit an anti-
body response may have utility in cancer screening, diagnosis or in
establishing prognosis, and in immunotherapy against the disease.
There are several approaches for the detection of tumour antigens
that induce an immune response35. A number of antigens have been
detected by screening expression libraries with patient sera36–41 or,
more recently, by using a random peptide-library approach42. Multi-
ple proteins that induce autoantibodies that are specific for different
types of cancer have been identified using 2D gels to separate tumour
proteins, followed by western blotting and incubation with patient
sera43. For most antigenic proteins identified using this approach,
post-translational modifications contributed to the immune
response. In a study of lung cancer, sera from 60% of patients with
lung adenocarcinoma and from 33% of patients with squamous-cell
lung carcinoma, but from none of the non-cancer controls, exhibited
immunoglobulin-g-based reactivity against proteins identified as
glycosylated annexins I and II44. Microarrays that contain proteins
derived from tumour cells have the potential of substantially 
accelerating the pace of discovery of tumour antigens and yielding a
molecular signature for immune responses directed against protein
targets in different types of cancer33.
The increased emphasis on proteomics for disease investigations
is stimulating a reassessment of strategies for sample procurement
and preservation to render them compatible with proteomics,
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Figure 3 Activity-based protein profiling. This chemical strategy is used to monitor changes
in the functional state of enzyme superfamilies directly in complex proteomes47. a, The
method uses chemical probes that comprise three general elements: an active-site-
directed reactive group (shown here as an ethoxy fluorophosphonate group that targets the
serine hydrolase class of enzymes), a linker (shown here as a polyethylene glycol group)
and a tag for the visualization of active enzymes (shown here as a rhodamine group). Active
enzymes are denoted by shapes with open active sites; their inactive counterparts have
their active sites shaded in black. b, Labelled proteome activity profile. Representative in-
gel fluorescence analysis of the secreted proteome (labelled with fluorescent pigment)
derived from invasive MUM-2B and non-invasive MUM-2C human melanoma cancer cells.
Enzyme activities selectively associated with either invasive cells (for example, urokinase) or
non-invasive cells (for example, sialic acid 9-O-acetylesterase or SAE) are noted.
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because of the inherent instability of proteins. For example, the man-
ner in which biological fluids such as serum or plasma are collected is
not ideally suited for proteomics. There is a need to reduce protein
degradation and other forms of modifications that may substantially
alter protein content and interfere with global profiling.
Disease-related functional proteomics
Although data obtained by various expression proteomics strategies
have functional relevance by uncovering altered levels or post-
translational modification states of proteins in disease, additional
technologies are needed for more direct functional analysis. This is
exemplified by the need to analyse protein complexes and their 
disruption in disease, to assay in a high-throughput fashion the activ-
ity of various classes of proteins, and to manipulate the levels and
activities of individual proteins, in a cellular context, to determine
their role in different biological processes and disease states.
Various strategies are currently in use for studies of protein 
complexes and protein–protein interactions (see review in this issue
by Fields and co-workers, page 208). So far, such strategies have been
applied to disease investigations on a limited basis, with a relatively
narrow focus on particular complexes. For example, using affinity
pull-down assays, 2D gels and mass spectrometry, myocardial 
protein kinase C; (PKC;) was found to be associated physically with
at least 36 other proteins with a multitude of functions. Cardiopro-
tection induced by activation of PKC; was found to be coupled with
dynamic modulation and recruitment of PKC;-associated
proteins45. Previously unrecognized functions of PKC; have 
relevance to heart function and heart disease. Clearly, at the present
time, most systematic studies of protein–protein interactions have
dealt with normal or physiological states, as the field is still in its early
stages and the merits of various technologies, particularly for disease
investigations, have yet to be fully appreciated.
Likewise, there has been limited application of activity-based 
proteomics to disease investigations, although the field itself is still in
its early stages46–48. Activity-based assays of normal and disease tissue
have substantial relevance to the study of disease, but probably will be
limited to the analysis of one class of proteins at a time. The potential
contribution of this technique to the measurement of global dynam-
ics in protein function is illustrated by the application of a chemical
proteomics strategy to quantitatively compare enzyme activities
across normal and disease tissue47 (Fig. 3). A global analysis of the
activity, subcellular distribution and glycosylation state for the serine
hydrolase superfamily in a panel of human breast and melanoma cell
lines resulted in the identification of a cluster of proteases lipases and
esterases that distinguished cancer lines based on tissue of origin.
Remarkably, the majority of these enzyme activities were downregu-
lated in the most invasive cancer lines examined, which instead
upregulated a distinct set of secreted and membrane-associated
enzyme activities.
Approaches are being developed or implemented to allow direct-
ed protein manipulations other than by decreasing or increasing
overall amounts of protein, as can be done by gene manipulations.
One advantage of these approaches is the ability to inactivate a specif-
ic site in a protein in a time-dependent and localization-restricted
manner, as with chromophore-assisted laser inactivation (CALI).
Such inactivation allows assessment of the disease relevance of the
site and provides a means to revert a cellular phenotype to a more
normal state49 (Fig. 4). Inactivation of protein targets involved in 
different signal-transduction pathways in cancer using CALI has
been demonstrated49.
Contributions of proteomics to studies of pathogens
Despite earlier predictions to the contrary, infectious diseases remain
as a leading cause of death worldwide. A complicating factor in 
therapy for infectious disease is the development of resistance to
commonly used drugs (for example, as has occurred in tuberculosis),
which heightens the need for developing effective new therapies.
Interest in the application of proteomics to microbiology goes back at
least two decades, with the pioneering work of Fred Neidhardt to
characterize protein expression patterns in Escherichia coli under 
different growth conditions50. The complete sequencing of a number
of microbial genomes has provided a framework for identifying 
proteins encoded in these genomes using mass spectrometry. A case
in point is the sequencing of the genome of the malaria parasite 
Plasmodium falciparum, which has provided a basis for conducting
comparative proteomics studies of this pathogen, leading to the 
identification of new potential drug and vaccine targets51,52. Aside
from comprehensive identification of microbial proteins, 
proteomics is relevant to numerous aspects of microbial disease
pathogenesis and treatment53–57 (Table 1).
Contribution of proteomics to drug development
There is currently a burgeoning interest in proteomics on the part of
the pharmaceutical industry, evidenced by implementation of 
proteomics programmes by most major pharmaceutical companies.
The notion has been advanced that, as the vast majority of drugs 
target proteins, proteomics should have substantial utility for drug
development. But the industry has so far adopted a cautious attitude,
and it is too early to make a critical assessment of the contributions of
proteomics to drug development, relative to other approaches. The
caution stems from the prior heavy investment in genomics and
other approaches and some uncertainty surrounding the 
adequacy and scalability of proteomics to meet the needs of the 
pharmaceutical industry. Provided suitable technology platforms
become available, the use of proteomics may permeate numerous
aspects of drug development, by identifying new targets and 
facilitating assessment of drug action and toxicity both in the 
preclinical and clinical phases.
Several published studies illustrate the application of functional
proteomics for identification of regulated targets in specific 
pathways. Lewis et al.58 have combined functional proteomics with
selective activation and inhibition of mitogen-activated protein
kinase (MAPK) kinase (MKK), in order to identify cellular targets
regulated by the MKK/ERK cascade. Twenty-five targets of this 
signalling pathway were identified, of which only five were previously
characterized as MKK/ERK effectors. The remaining targets suggest
new roles for this signalling cascade in cellular processes of nuclear
transport, nucleotide excision repair, nucleosome assembly, 
membrane transport and cytoskeletal regulation.
In another study to identify proteases most suitable for drug 
targeting, an automated microtitre-plate assay was modified to allow
detection of the four main classes of proteases in tissue samples
(matrix metalloproteases, cathepsins, and the cell serine proteases,
tryptase and chymase)59. Fifteen sets of colorectal carcinoma biopsies
representing primary tumour, adjacent normal colon and liver
metastases were screened for protease activity. Matrix metallopro-
teases were expressed at higher levels in the primary tumour than in
adjacent normal tissue. The mast cell proteases, in contrast, were
found at very high levels in adjacent normal tissue, but were not
detectable in the metastases. Cathepsin B activity was significantly
higher in the primary tumour, and highest in the metastases. The
proteases detected by activity assays were then localized in biopsy 
sections by immunohistochemistry. Mast cell proteases were abun-
dant in adjacent normal tissue, because of infiltration of the lamina
propria by mast cells. Matrix metalloproteases were localized to the
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Table 1 Targeted proteomic approaches to microbial pathogens
• Characterization of submicrobial proteomes (for example, secreted proteins, 
surface proteins and immunogenic proteins)
• Comparative analysis of different strains 
• Comparative analysis of different physiological states
• Identification of proteins related to pathogenicity
• Identification of proteins involved in host–pathogen interactions
• Evaluation of mechanisms of action of antimicrobials
© 2003 Nature Publishing Group
tumour cells themselves, whereas cathepsin B was expressed pre-
dominantly by macrophages at the leading edge of invading tumours.
Such activity-based screening provides a basis for selecting targets
in the development of inhibitors to specific proteases. Protein
biochips potentially could provide a high-throughput platform for
target identification. Biochips developed for interaction studies
could be important in lead-compound optimization and could
accelerate drug development by allowing efficient evaluation of lead
compounds for specificity and selectivity in binding to drug targets.
Proteomics also may provide increased efficiency of clinical trials
through the availability of biologically relevant markers for drug 
efficacy and safety.
Organizing proteomics initiatives
It is clear that while some progress has been made in disease 
proteomics, the field is still in its infancy. Knowledge of the sequence
of the human genome has provided a framework for genomic
approaches to unravel disease processes. A similar knowledge of the
human proteome is currently lacking. Developing a comprehensive
knowledge framework of the proteome is considerably more 
complex than sequencing the human genome. Ideally, such a 
proteome framework would encompass knowledge of all human
proteins, from their sequence to their post-translational modifica-
tions, to their interactions among each other, their cellular and sub-
cellular distribution, and their temporal pattern of expression.
Although such an exhaustive framework will not materialize in the
foreseeable future, more modest goals may well be within reach. 
To that effect, there is a need to begin an organized effort, the goals
of which include developing an infrastructure in proteomics that
would substantially facilitate unravelling the complexity of the pro-
teome in health and in disease. The Human Proteome Organisation
(HUPO, http://www.hupo.org) was founded to regroup scientists in
the public and private sectors engaged throughout the world in 
various aspects of proteomics. HUPO’s mission is threefold: to 
consolidate national and regional proteome organizations into a
worldwide organization; to engage in scientific and educational
activities to encourage the spread of proteomics technologies and
disseminate knowledge pertaining to the human proteome and that
of model organisms; and to assist in the coordination of public 
proteome initiatives aimed at characterizing specific tissue and cell
proteomes. Initiatives currently in the pilot phase include an 
international effort to identify proteins detectable in normal serum
and plasma and their range of variation with age, ethnicity and 
physiological state, and a liver proteome study to identify proteins
expressed in the liver. These initiatives have attracted substantial
interest and will be integrated with efforts in protein informatics to
achieve data standardization on the one hand, and data curation on
the other.
Concluding remarks
Proteome alterations in disease may occur in many different ways
that are not predictable from genomic analysis, and it is clear that a
better understanding of these alterations will have a substantial
impact in medicine. A useful repertoire of proteomics technologies is
currently available for disease-related applications, although 
further technological innovations would be beneficial to increase 
sensitivity, reduce sample requirement, increase throughput and
more effectively uncover various types of protein alterations such as
post-translational modifications. The use of these technologies 
will likely expand substantially, particularly to meet the need for 
better diagnostics and to shorten the path for developing effective
therapy. ■
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Figure 4 Chromophore-assisted laser inactivation. This technology involves the
generation of short-lived radicals that induce covalent modifications at spatially
restricted sites on a protein49. A transient functional inactivation occurs if the radicals
modify amino acids of the target protein that have a functional role. A target protein (a)
is complexed with a ligand (yellow; for example, antibody, antibody fragments such as
scFv and Fab, peptide, nucleic acid aptamers or small molecules) labelled with dye
molecules (green; for example, malachite green or fluorescein) (b). The complex is
irradiated with laser or incoherent light (red lightning), leading to the generation of
reactive species (concentric circles) that travel a short distance (c). The reactive
species in turn lead to modifications (black) of nearby amino acids (d). If the modified
amino acids are responsible for a function, that particular functional protein domain
will be inactivated, leaving the other functional domains intact.
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